Abbott Laboratories is planning to increase production of its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the coming years, Reuters reported July 16.

A study published in the New England Journal of Medicine July 18 suggests it may be time for the medical community to rethink its perception of diastolic blood pressure, which has long been considered inferior to systolic BP as a measure of cardiovascular wellness.

Massachusetts-based Azurity Pharmaceuticals announced July 10 it had received FDA approval for Katerzia Oral Suspension, making the drug the first and only FDA-approved amlodipine oral suspension to hit the commercial market.

Multivitamins and the bulk of nutritional supplements do little to protect heart health, in some cases increasing a person’s risk for CV events, an analysis published in the Annals of Internal Medicine has found.

Research published in Hypertension July 1 suggests a vitamin D deficiency in early childhood could translate to an increased risk of high blood pressure in adolescence.

CMS on July 2 announced its finalized national coverage policy for ambulatory blood pressure monitoring—one that extends coverage to patients with suspected masked hypertension and aligns CMS’ BP thresholds with the latest society guidelines.

A lack of formal training in nutrition could significantly limit how physicians practice, according to an editorial published in JAMA Internal Medicine this month, in some cases leading them to recommend risky treatments to patients in lieu of dietary counseling that might be just as effective.

A bariatric surgeon at the Ohio State Wexner Medical Center is advocating for a new set of clinical guidelines that would extend eligibility for weight loss surgery to thousands more patients struggling with their weight.